Prostate-specific membrane antigen (PSMA), a transmembrane glycoprotein, is frequently overexpressed in prostate cancer cells and is associated with early recurrence, resistance to castration therapy, and poor prognosis [2,3]. This evidence concerns the gene FOLH1 and prostate carcinoma.